Quick Answer: How Is Radiation Used for Prostate Cancer?
Radiation therapy can cure many localized and locally advanced prostate cancers, can be used after prostatectomy when cancer risk remains or PSA rises, and can relieve symptoms from metastatic disease.
Modern prostate radiation is not simply “one beam every day.” Options include IMRT/VMAT with image guidance, moderate hypofractionation, SBRT/ultra-hypofractionation, LDR or HDR brachytherapy, and proton therapy.
Which approach is appropriate depends on the man’s prostate-cancer risk group, PSA, Grade Group, stage, urinary function, anatomy, previous treatment, life expectancy and whether androgen deprivation therapy (ADT) should be added.
For many intermediate-risk cancers, radiation is combined with about 4–6 months of ADT. For high-risk localized disease, current EAU guidance recommends modern external-beam radiation plus 2–3 years of ADT.
What Is Radiation Therapy?
Radiation therapy uses ionizing radiation to damage the DNA of cancer cells so they can no longer continue dividing normally.
For prostate cancer, radiation can be delivered:
- from a machine outside the body — external-beam radiation therapy (EBRT);
- from radioactive material placed temporarily or permanently inside the prostate — brachytherapy;
- after surgery to the prostate bed — postoperative/salvage radiotherapy; or
- to metastatic sites to control cancer or relieve symptoms.
Radiotherapy is different from diagnostic X-rays or CT scans. Diagnostic imaging uses much smaller radiation doses to create images; therapeutic radiation delivers a carefully planned cancer-killing dose.
Is Radiation Only for Late-Stage Prostate Cancer?
No.
The legacy version of this page suggested radiation usually begins near the end of stage II or later. That is incorrect.
Radiotherapy can be used with curative intent in localized prostate cancer, including selected stage I, II and III disease.
It also has important roles:
- after prostatectomy;
- for biochemical recurrence;
- for regional lymph-node disease;
- for selected metastatic presentations; and
- for relief of painful or threatening metastases.
See our prostate cancer stages guide for how stage differs from risk group.
Does Every Localized Prostate Cancer Need Radiation?
No.
For men with low-risk prostate cancer, current EAU guidance generally favors active surveillance when life expectancy is greater than about ten years and the patient is suitable for surveillance.
That means the first question for low-risk disease is often not “Which radiation technique should I choose?” but:
“Do I need treatment now?”
Radiation becomes especially important when treatment is appropriate because of intermediate-, high-risk or locally advanced disease, or when a patient chooses definitive radiation rather than surgery.
Main Types of Prostate Cancer Radiation
| Type | How it works | Typical role | Key feature |
|---|---|---|---|
| IMRT / VMAT + IGRT | Computer-controlled photon beams shape dose around the prostate. | Standard external-beam approach across many localized/high-risk settings. | Highly conformal and widely available. |
| Moderate hypofractionation | Larger dose per visit over fewer visits. | Common modern standard for localized disease. | Usually about 4–6 weeks. |
| SBRT / ultra-hypofractionation | Very high precision with only a few fractions. | Selected localized patients, especially favorable-risk disease. | Often 5–7 treatments. |
| LDR brachytherapy | Permanent radioactive seeds implanted in prostate. | Selected low/favorable intermediate disease; boost in higher-risk disease. | Radiation delivered internally over weeks/months. |
| HDR brachytherapy | Temporary radioactive source delivered through catheters. | Selected monotherapy or boost. | No radioactive source remains afterward. |
| Proton therapy | Charged particles deliver dose with minimal exit radiation. | Specialized alternative to photon EBRT. | No proven universal clinical superiority over modern IMRT. |
1. IMRT and VMAT
Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) are modern forms of photon radiation.
A computer adjusts radiation intensity from many angles so that the prescribed dose conforms closely to:
- the prostate;
- seminal vesicles when appropriate;
- the prostate bed after surgery; and
- pelvic lymph nodes when they are included.
The goal is to maintain excellent cancer coverage while reducing unnecessary dose to:
- rectum;
- bladder;
- bowel;
- urethral structures; and
- other nearby tissues.
Current EAU guidance identifies IMRT/VMAT plus image-guided radiotherapy (IGRT) as the standard external-beam technique for localized and high-risk prostate cancer.
2. What Is Image-Guided Radiation Therapy (IGRT)?
The prostate can move slightly from day to day because bladder and rectal filling change.
IGRT checks prostate position before or during treatment using techniques such as:
- daily imaging;
- cone-beam CT;
- implanted fiducial markers;
- electromagnetic tracking; or
- other image-guidance systems.
Accurate daily localization allows smaller treatment margins and helps protect normal tissue.
3. Moderate Hypofractionation
Older prostate-radiation courses often lasted eight or nine weeks.
Modern evidence shows that many patients can safely receive a slightly larger dose per treatment over a shorter period.
Current EAU examples include:
- 60 Gy in 20 fractions over approximately 4 weeks; or
- 70 Gy in 28 fractions over approximately 6 weeks.
These schedules provide cancer control comparable with longer conventional courses in appropriately selected patients.
4. SBRT / Ultra-Hypofractionated Radiation
Stereotactic body radiation therapy (SBRT) gives a very precise high dose in a small number of fractions.
Current EAU guidance allows selected favorable-intermediate-risk patients with suitable urinary function to receive regimens such as:
- 36.25 Gy in 5 fractions; or
- 42.7 Gy in 7 fractions.
SBRT requires excellent:
- treatment planning;
- immobilization;
- image guidance;
- motion management; and
- normal-tissue dose constraints.
Very short schedules are attractive for convenience, but they should not be selected solely because a patient wants fewer visits.
5. Brachytherapy: Radiation From Inside the Prostate
Brachytherapy places the radiation source directly inside the prostate.
There are two major approaches.
LDR Brachytherapy
Low-dose-rate brachytherapy permanently implants radioactive seeds, usually containing iodine-125 and in some centers palladium-103 or cesium-131.
LDR can be:
- monotherapy in selected favorable disease; or
- a boost combined with external-beam radiation in selected unfavorable intermediate- or high-risk disease.
HDR Brachytherapy
High-dose-rate brachytherapy temporarily places catheters in the prostate. A radioactive source—typically iridium-192—is passed through those catheters for several minutes and then removed.
No radioactive material remains in the patient after HDR treatment.
For a complete explanation, see our prostate brachytherapy and seed implant guide.
6. Proton Therapy
Protons deposit most of their energy at a defined depth—the Bragg peak—and then have a sharp dose fall-off.
This can reduce the radiation dose received by some normal tissues beyond the prostate.
However, a physical dose advantage does not automatically mean better clinical outcomes.
The randomized PARTIQoL trial compared proton therapy with modern IMRT in 450 men with localized prostate cancer and found no significant difference in quality of life or progression-free survival after about five years.
Current EAU guidance therefore states that proton treatment has not demonstrated an advantage over less resource-intensive IMRT/VMAT in that population.
See our detailed proton therapy vs IMRT guide.
Radiation by Prostate Cancer Risk Group
Low-Risk Disease
For suitable men with life expectancy greater than about ten years, current EAU guidance recommends active surveillance as standard of care.
If definitive treatment is nevertheless appropriate because of individual factors or informed preference, radiation can be discussed alongside surgery and other established approaches.
Favorable Intermediate-Risk Disease
Options may include:
- IMRT/VMAT;
- moderate hypofractionation;
- selected SBRT;
- LDR brachytherapy; or
- selected HDR brachytherapy.
Whether ADT is necessary depends on the exact favorable/unfavorable features and treatment approach.
Unfavorable Intermediate-Risk Disease
Current EAU guidance recommends modern IMRT/VMAT + IGRT combined with approximately 4–6 months of ADT.
A brachytherapy boost can be considered in men with good urinary function.
High-Risk Localized Disease
Current EAU guidance recommends:
IMRT/VMAT + IGRT + long-term ADT for approximately 2–3 years.
In selected men with good urinary function, LDR or HDR brachytherapy can be added as a boost.
Selected MRI-visible dominant intraprostatic tumors can also receive a focal radiation boost while normal-tissue limits are respected.
Locally Advanced or Node-Positive Disease
Radiation often becomes part of a multimodal strategy involving:
- prostate radiation;
- pelvic nodal radiation in selected settings;
- long-term ADT; and
- additional systemic treatment such as abiraterone in selected high-risk/node-positive disease.
The treatment plan should be determined by staging, nodal status, Grade Group and overall health.
Why Is ADT Combined With Radiation?
ADT reduces androgen-receptor signaling and can make prostate cancer more responsive to radiation.
Randomized evidence has shown improved cancer outcomes when ADT is added for appropriately selected intermediate- and high-risk disease.
The required duration differs:
| Clinical setting | Typical hormone-therapy approach |
|---|---|
| Favorable intermediate risk | ADT may sometimes be omitted depending on risk details and treatment plan. |
| Unfavorable intermediate risk | Usually short-term ADT, approximately 4–6 months. |
| High-risk localized disease | Long-term ADT, generally 2–3 years. |
| Selected very high-risk / cN1M0 disease | Long-term ADT plus additional systemic treatment may be indicated. |
ADT has its own effects on sexual function, bone, muscle, glucose, lipids and cardiovascular health. Read our complete prostate cancer hormone therapy guide.
Should Pelvic Lymph Nodes Be Irradiated?
Not every patient needs pelvic-node radiation.
The decision depends on the estimated probability of nodal involvement and the clinical setting.
For high-risk disease, studies suggest potential disease-control benefit in selected men, but whole-pelvic treatment exposes more normal tissue and can increase urinary or bowel toxicity.
When pelvic lymph nodes are treated, current AUA/ASTRO guidance recommends modern IMRT-based techniques.
Radiation After Radical Prostatectomy
Radiation can also be used after prostate removal.
Two broad situations exist:
Adjuvant Radiation
Radiation is given after surgery because pathology shows very high-risk features even though PSA is undetectable.
Routine adjuvant radiation is no longer required for most men with undetectable postoperative PSA because modern trials support close PSA monitoring followed by early salvage treatment when needed.
Selected patients with particularly adverse pathology may still be considered for adjuvant treatment.
Early Salvage Radiation
Salvage radiation is given when PSA persists or starts rising after surgery.
Current salvage guidance emphasizes treating while PSA remains low because cure rates decline as PSA rises.
For a detailed explanation, see prostate cancer recurrence and salvage treatment.
Can Radiation Treat Metastatic Prostate Cancer?
Yes, but the goal depends on the situation.
Radiation to the Prostate in Selected Metastatic Disease
Selected men with newly diagnosed low-volume metastatic hormone-sensitive prostate cancer can benefit from radiation to the primary prostate as part of systemic treatment.
Metastasis-Directed Radiation
SBRT can be used for selected men with a small number of metastatic deposits, particularly in carefully staged oligometastatic recurrence.
This does not prove that all microscopic metastatic disease has been eliminated.
Palliative Radiation
Radiation is highly effective for symptoms such as:
- painful bone metastases;
- bleeding;
- local pelvic pain;
- threatened fracture; or
- spinal-cord compression as part of emergency treatment.
How Is External-Beam Radiation Planned?
Before treatment begins, the radiation oncology team performs a planning session called simulation.
This can include:
- planning CT;
- MRI fusion or prostate MRI;
- bladder and rectal preparation instructions;
- fiducial markers in selected patients;
- immobilization devices;
- contouring of prostate, seminal vesicles, nodes and normal organs; and
- computer optimization of radiation dose.
The final treatment plan is checked by the radiation oncologist, physicist and treatment team before therapy begins.
How Long Does Each Radiation Visit Take?
The actual radiation beam is usually delivered within minutes.
But the complete appointment is longer because accurate positioning and image guidance take time.
The number of visits varies widely:
- around 20–28 treatments with common moderate hypofractionation;
- as few as 5–7 treatments with selected SBRT schedules;
- longer schedules in selected conventional treatment plans; or
- one implant procedure for some LDR brachytherapy treatments.
So prostate radiation does not routinely continue for two years. Long treatment durations such as 2–3 years refer to accompanying ADT in high-risk disease—not daily radiation.
What Are the Common Short-Term Side Effects?
EAU reports that urinary and gastrointestinal effects are common during treatment, but most acute toxicity improves afterward.
Urinary Effects
- frequency;
- urgency;
- nocturia;
- burning with urination;
- weaker stream;
- temporary retention; and
- occasionally blood in the urine.
Bowel / Rectal Effects
- looser stools;
- increased bowel frequency;
- rectal urgency;
- proctitis/irritation;
- gas;
- mucus; and
- minor rectal bleeding.
Fatigue
Fatigue is common during a multi-week radiation course and can be more noticeable when radiation is combined with ADT.
What Are the Possible Long-Term Side Effects?
Erectile Dysfunction
Erections are often preserved immediately after radiation, but erectile function may gradually decline over months or years.
Risk is influenced by:
- age;
- erectile function before treatment;
- diabetes and vascular disease;
- radiation dose;
- smoking;
- ADT use; and
- other medications.
Late Urinary Problems
Some men develop persistent urgency, frequency, bleeding or urethral narrowing.
Severe urinary injury is uncommon with modern techniques but can require urological treatment.
Late Rectal Problems
Chronic radiation proctitis can cause:
- rectal bleeding;
- urgency;
- discomfort; or
- changes in bowel function.
Serious rectal injury is uncommon with properly planned modern radiation.
Urinary Incontinence
Major incontinence is usually less common after primary radiotherapy than after prostatectomy, but it can occur, particularly after previous prostate surgery or salvage procedures.
Does Radiation Cause Hair Loss?
Radiation causes hair loss only in the area actually receiving radiation.
Prostate radiation therefore does not cause scalp hair loss.
Hair in the lower pelvic treatment field may thin temporarily depending on beam arrangement and dose.
Can Radiation Cause Another Cancer Years Later?
Ionizing radiation carries a small long-term risk of causing another malignancy.
NCI notes increased long-term bladder and gastrointestinal second-cancer risk after prostate radiation.
For an individual patient, this risk must be balanced against:
- the chance of curing the prostate cancer;
- age and life expectancy;
- competing health risks; and
- alternative treatments.
The possibility of a second cancer many years later is not a reason to dismiss effective radiation when it is otherwise the right cancer treatment.
Radiation vs Surgery
There is no universal “best” treatment for every localized prostate cancer.
Both surgery and radiation can produce excellent cancer control when used appropriately.
| Issue | Radiation | Radical prostatectomy |
|---|---|---|
| Treatment approach | Non-surgical local treatment | Surgical removal of prostate |
| Urinary incontinence | Usually lower immediate risk with primary RT | More common after surgery, especially early |
| Erectile dysfunction | Often gradual over time | Often immediate, with recovery depending on nerve-sparing and baseline function |
| Bowel effects | More relevant than after surgery | Usually less prominent |
| PSA afterward | Falls gradually; prostate remains | Should become very low/undetectable |
| Need for additional treatment | Some men need systemic/salvage therapy | Some men need salvage radiation and/or systemic therapy |
Age alone should not decide between the treatments. Cancer risk, urinary symptoms, sexual function, bowel health, comorbidity and personal priorities matter.
What Happens to PSA After Radiation?
Because the prostate remains in place after radiation, PSA is not expected to become immediately undetectable.
EAU notes that PSA falls more slowly after radiation than after prostatectomy and can take three years or more to reach its lowest point.
A PSA nadir below 0.5 ng/mL is associated with favorable outcomes, although no single nadir threshold perfectly predicts cure.
What Is PSA Bounce?
A temporary PSA rise followed by another decline can occur after radiation, especially after brachytherapy.
This is called a PSA bounce.
A bounce does not automatically mean prostate cancer has returned.
How Is Biochemical Recurrence Defined After Radiation?
The commonly used Phoenix definition is:
PSA rise of 2 ng/mL or more above the post-radiation PSA nadir.
This definition also applies when ADT was used with radiotherapy.
When recurrence is suspected, imaging such as PSMA PET and MRI may help determine whether disease is local, nodal or metastatic.
Can Prostate Cancer Be Retreated After Radiation?
Sometimes.
Men with biopsy-proven recurrence still confined to the prostate may be candidates for selected salvage treatment at experienced centers, such as:
- salvage prostatectomy;
- salvage LDR/HDR brachytherapy;
- salvage SBRT;
- cryotherapy; or
- HIFU in selected specialist/trial settings.
Salvage therapy after previous radiation carries more urinary, erectile and rectal risk than primary treatment, so careful staging and biopsy confirmation are important.
Questions to Ask a Radiation Oncologist
- What is my exact risk group and stage?
- Do I actually need definitive treatment now?
- Why do you recommend radiation rather than surgery or surveillance?
- Should I receive IMRT/VMAT, SBRT, brachytherapy or another technique?
- How many fractions will I need?
- Do I need ADT, and for how long?
- Should my pelvic lymph nodes be treated?
- What are my baseline urinary and bowel risks?
- How will treatment affect erections?
- What dose will my rectum and bladder receive?
- How will PSA be interpreted after treatment?
- If the cancer returns, what salvage options would remain?
Prostate radiation has changed dramatically. Modern treatment is not the old concept of a broadly aimed radioactive beam given for an undefined period. IMRT, VMAT, image guidance, MRI-based planning, hypofractionation and brachytherapy allow the treatment team to shape radiation much more accurately.
I would also avoid choosing a radiation technique simply because it sounds newer. Proton therapy, for example, has a genuine physical dose advantage in some plans, but randomized evidence has not shown better quality of life or cancer control than modern IMRT for typical low- or intermediate-risk localized disease.
The most important questions are usually the cancer’s risk group, whether radiation is actually needed, whether ADT should be added, whether pelvic nodes require treatment and what the patient’s baseline urinary function is.
Finally, PSA after radiation behaves differently from PSA after surgery. The prostate remains in place, PSA falls gradually, and a temporary PSA bounce can occur. Patients should therefore avoid interpreting one small PSA rise as definite recurrence without reviewing the overall trend.
Medical References
European Association of Urology. Prostate Cancer Guidelines, 2026: IMRT/VMAT + IGRT, hypofractionation, SBRT, brachytherapy, proton therapy, ADT combinations, high-risk treatment and radiation follow-up.
American Urological Association / ASTRO. Clinically Localized Prostate Cancer Guideline, amended 2026: radiation options, pelvic-node treatment and ADT with high-risk radiation.
National Cancer Institute. Prostate Cancer Treatment PDQ: external-beam radiation, brachytherapy, radiopharmaceutical therapy and radiation adverse effects.
European Association of Urology. Follow-up chapter, 2026: PSA decline after radiotherapy and Phoenix definition of biochemical recurrence.
Last evidence update: September 2026.
Medical information notice: Prostate-cancer radiation must be individualized by a radiation oncology team. Risk group, urinary function, anatomy, previous treatment, life expectancy and the need for ADT or additional systemic therapy all influence the safest and most effective treatment plan.